News
First Commercial Sales: Humacyte commenced its commercial launch of Symvess in late February 2025 after the first commercial batch was released by the FDA. The first commercial shipments containing ...
Intracranial GCA appears to be more common than previously thought and is linked to higher rates of stroke and mortality.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results